Vimarsana
Biggest News Aggregation in the World

Practical Guidelines News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Stay updated with breaking news from Practical Guidelines. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.

Top News In Practical Guidelines Today - Breaking & Trending Today

Nippon Shinyaku : Vyxeos® Combination for I.V. Injection Receives Approval for the Treatment of High-risk AML in Japan -March 26, 2024 at 03:06 am EDT - Vimarsana News

Nippon Shinyaku : Vyxeos® Combination for I.V. Injection Receives Approval for the Treatment of High-risk AML in Japan -March 26, 2024 at 03:06 am EDT

NEWS RELEASE March 26, 2024 Vyxeos® Combination for I.V. Injection Receives Approval for the Treatment of High-risk...

AstraZeneca's Tagrisso plus chemotherapy appoved for lung cancer in the US - Vimarsana News

AstraZeneca's Tagrisso plus chemotherapy appoved for lung cancer in the US

AstraZeneca's Tagrisso approved in the US for EGFRm non-small cell lung cancer with chemotherapy. FLAURA2 trial results show significant benefit.

India statistics: Concerns around sampling design of govt surveys not tenable: MoSPI minister - Vimarsana News

India statistics: Concerns around sampling design of govt surveys not tenable: MoSPI minister

The concerns regarding the National Sample Surveys' sampling design are deemed invalid by Rao Inderjit Singh, Minister of State for Ministry of Statistics and Programme Implementation. He argues that the conclusions drawn from the surveys were based on faulty approaches and inapplicable methods. The ministry follows UN guidelines for designing household survey samples and ensures statistically significant estimates.

EPKINLY™ (epcoritamab) Approved by Japan Ministry of Health, Labour and Welfare as the First Bispecific Antibody to Treat Adults Patients with Certain Types of Relapsed or Refractory (R/R) Large B-Cell Lymphoma (LBCL) - Vimarsana News

EPKINLY™ (epcoritamab) Approved by Japan Ministry of Health, Labour and Welfare as the First Bispecific Antibody to Treat Adults Patients with Certain Types of Relapsed or Refractory (R/R) Large B-Cell Lymphoma (LBCL)

Subcutaneous EPKINLY™ is the first and only bispecific antibody approved in Japan to treat adult patients with certain types of relapsed/refractory large B-cell lymphoma after two or more lines...

EPKINLYTM (epcoritamab) Approved by Japan Ministry of Health, Labour and Welfare as the First Bispecific Antibody to Treat Adults Patients with Certain Types of Relapsed or Refractory (R/R) Large B-Cell Lymphoma (LBCL) - Vimarsana News

EPKINLYTM (epcoritamab) Approved by Japan Ministry of Health, Labour and Welfare as the First Bispecific Antibody to Treat Adults Patients with Certain Types of Relapsed or Refractory (R/R) Large B-Cell Lymphoma (LBCL)

Media Release Subcutaneous EPKINLYTM is the first and only bispecific antibody approved in Japan to treat adult patients with certain types of relapsed/refractory large B-cell lymphoma after two...